Veradigm to Use AI for Real-World Insights on GLP-1 Therapy in Diabetes & Obesity

Veradigm's platform will extract information directly from clinician notes, including comorbidities, treatment responses, and social health determinants affecting adherence. 

Chicago-based Veradigm Life Sciences has announced plans to deploy artificial intelligence (AI) on de-identified electronic health record (EHR) data to generate real-world evidence (RWE) about the use of GLP-1 receptor agonists in patients with diabetes and obesity. 

The initiative aims to uncover critical insights into treatment patterns, side effects, and social factors influencing therapy adherence by analysing data from the Veradigm Network, which includes over 152 million patient records.

Addressing Data Gaps in a Growing Therapeutic Area

GLP-1 therapies have gained widespread popularity for managing diabetes and obesity, yet significant knowledge gaps remain about their real-world use. 

Veradigm's AI-powered approach will enable researchers to access information that traditionally required extensive manual review. This includes reasons for treatment discontinuation, identification of side effects like gastrointestinal symptoms, and detection of compounded or unapproved formulations.

"AI-powered curation allows us to unlock clinically meaningful insights from millions of patient records — insights that have traditionally been hidden in unstructured and semi-structured fields of EHR systems," said Stuart Green, Senior Vice President and General Manager at Veradigm. 

"This is especially critical for GLP-1 therapies, where understanding why patients discontinue, or which side effects matter most, can significantly improve patient outcomes and therapeutic strategy."

Veradigm's platform will extract information directly from clinician notes, including comorbidities, treatment responses, and social health determinants affecting adherence. 

The company notes that its nationally representative, standardised, and de-identified data is clinically validated and suitable for life sciences research, regulatory discussions, and value-based care initiatives.

With this AI-powered initiative, Veradigm aims to support healthcare stakeholders in optimising treatment strategies and improving health outcomes for patients using GLP-1 therapies.

Stay tuned for more such updates on Digital Health News.